Jade Biosciences, Inc. (NASDAQ:JBIO) Receives $51.75 Consensus Target Price from Analysts

Jade Biosciences, Inc. (NASDAQ:JBIO) has received a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $51.75.

JBIO has been the topic of a number of research analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $47.00 target price on shares of Jade Biosciences in a report on Tuesday, June 2nd. Piper Sandler set a $55.00 price target on Jade Biosciences in a report on Tuesday, June 2nd. Wedbush increased their price objective on Jade Biosciences from $45.00 to $47.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price objective on shares of Jade Biosciences in a research note on Tuesday, August 11th. Finally, UBS Group began coverage on shares of Jade Biosciences in a research report on Monday, June 15th. They set a “buy” rating and a $45.00 target price on the stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new stake in Jade Biosciences during the second quarter worth about $154,000. Legal & General Group Plc bought a new position in Jade Biosciences during the second quarter valued at about $29,000. Rhumbline Advisers acquired a new position in Jade Biosciences in the 2nd quarter valued at approximately $445,000. Russell Investments Group Ltd. acquired a new position in Jade Biosciences in the 2nd quarter valued at approximately $31,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Jade Biosciences in the 2nd quarter worth approximately $114,000.

Jade Biosciences Price Performance

JBIO stock opened at $19.90 on Monday. Jade Biosciences has a 52-week low of $6.91 and a 52-week high of $28.00. The company has a 50-day moving average of $21.35 and a two-hundred day moving average of $19.42. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -10.36 and a beta of 1.45.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Equities analysts expect that Jade Biosciences will post -2.84 EPS for the current fiscal year.

About Jade Biosciences

Jade Biosciences, Inc is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small?molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.